Financial Report: Pfizer 4Q

Pfizer 4Q

4Q Revenues: $16.5 billion (+34%)

4Q Earnings: $767 million (+188%)

FY Revenues: $50.0 billion (+4%)

FY Earnings: $8.6 billion (+7%)

Comments: Pfizer completed its acquisition of Wyeth in the quarter. U.S. revenues were $7.4 billion in the quarter (+42%). International revenues were $9.1 billion (+28%), reflecting 21% operational growth and a 7% favorable impact of foreign exchange. 4Q09 results were favorably impacted by $3.3 billion, or 27%, due to the addition of Wyeth products, $419 million, or 3%, for Pfizer products, and $469 million, or 4%, due to foreign exchange. Biopharmaceutical revenues in the quarter were 14.6 billion (+30%). For the year, revenues were favorably impacted by approximately $3.3 billion (+7%) with the addition of Wyeth products, $247 million (+1%) due to Pfizer products, and unfavorably impacted by $1.8 billion, (-4%), due to foreign exchange. U.S. revenues were $21.7 billion (+7%) and International revenues were $28.3 billion (+1%).